We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    CUV029
Previous Study | Return to List | Next Study

Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00979745
Recruitment Status : Completed
First Posted : September 18, 2009
Results First Posted : October 12, 2021
Last Update Posted : October 12, 2021
Information provided by (Responsible Party):
Clinuvel Pharmaceuticals Limited

Brief Summary:

Afamelanotide is a man-made drug being studied for use as a preventative medication for EPP sufferers. It is a synthetically produced analogue of human alpha melanocyte stimulating hormone (alpha-MSH) and is not yet available on the market.

The purpose of this study is to look at whether afamelanotide can reduce the number and severity of EPP symptoms when patients are exposed to light. This study will also look at how the drug is tolerated when taken by people with EPP.

The study will involve the use of an implant, which comes in the form of a small rod (approximately 2 cm x 0.15 cm) to be administered under the skin. The implant may contain the study drug afamelanotide or a placebo (inactive medication).

Over 450 subjects have been treated with afamelanotide to date with no serious safety concerns identified. For this study, afamelanotide has been formulated as a controlled release depot injection (implant). This means that the afamelanotide will be released slowly into the body over a few days. Once inserted, the implant will remain in the body after afamelanotide has been released and will slowly dissolve.

This study will help to provide more information about afamelanotide. This information will be used to determine the safety and efficacy (the ability of the drug to produce an effect) of this drug in EPP sufferers.

Up to 70 people will participate in this study from study sites across Europe.

Condition or disease Intervention/treatment Phase
Erythropoietic Protoporphyria Drug: Afamelanotide Drug: Placebo Phase 3

Detailed Description:


To determine whether afamelanotide can reduce the severity of phototoxic reactions in patients with EPP.


EPP is a genetic photosensitivity disorder where the mainstays of management are covering up from sunlight, systemic beta carotene and the use of controlled courses of UVR treatment. One of the mechanisms for the protective effects of UVR treatment is the increase in melanin content of the skin. UVR treatment causes DNA damage to skin cells and increases the risk for skin cancers, hence it is unwise for this to be used on a recurring basis. Afamelanotide, through its ability to stimulate melanin production without causing the DNA damage associated with UVR treatment, appears to be a promising agent to combat this distressing disorder.


This is a phase III, randomised, placebo controlled study to evaluate the safety and efficacy of subcutaneous implants of afamelanotide in patients suffering from EPP. The study will be performed in compliance with Good Clinical Practice (GCP) including the archiving of essential documents.


The target population consists of male and female participants. Up to 70 patients with diagnosed EPP (from past case history) and fulfilling the necessary inclusion/exclusion criteria will be enrolled. Potential study patients will be identified from each centre's records of patients with well characterised history (or documented diagnosis) of EPP.

Patients will be enrolled and will receive afamelanotide (16 mg implants) or placebo according to the following dosing regime:

  • Group A will be administered active implants on Days 0, 60, 120, 180 and 240.
  • Group B will be administered placebo implants on Days 0, 60, 120, 180 and 240.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)
Study Start Date : September 2009
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Arm Intervention/treatment
Experimental: Afamelanotide Drug: Afamelanotide
One 16mg subcutaneous implant every 2 months for 9 months.
Other Name: CUV1647

Placebo Comparator: Placebo Drug: Placebo
One 16mg subcutaneous implant every 2 months for 9 months.

Primary Outcome Measures :
  1. The Duration of Direct Sunlight Exposure Between 10:00 and 15:00 Hours on Days When Patients Did Not Report Phototoxicity-related Pain (Likert Pain Scale Score of 0) [ Time Frame: From baseline to Day 270 ]

Secondary Outcome Measures :
  1. Number of Phototoxic Reactions [ Time Frame: 9 months ]
  2. Quality of Life Measured by Patient Completed Questionnaire [ Time Frame: 9 months ]
  3. Free Protoporphyrin IX Level [ Time Frame: 9 months ]
  4. Treatment Emergent Adverse Events [ Time Frame: 9 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects with a diagnosis of EPP (confirmed by elevated free protoporphyrin in peripheral erythrocytes) of sufficient severity that they have requested treatment to alleviate their symptoms.
  • Aged 18 - 70 years (inclusive)
  • Written informed consent prior to the performance of any study-specific procedures.

Exclusion Criteria:

  • Any allergy to afamelanotide or the polymer contained in the implant or to lignocaine or other local anaesthetic to be used during the administration of study medication.
  • EPP patients with significant hepatic involvement.
  • Personal history of melanoma or dysplastic nevus syndrome.
  • Current Bowen's disease, basal cell carcinoma, squamous cell carcinoma, or other malignant or premalignant skin lesions.
  • Any other photodermatosis such as PLE, DLE or solar urticaria.
  • Any evidence of clinically significant organ dysfunction or any clinically significant deviation from normal in the clinical or laboratory determinations.
  • Acute history of drug or alcohol abuse (in the last 12 months).
  • Patient assessed as not suitable for the study in the opinion of the Investigator (e.g. noncompliance history, allergic to local anaesthetics, faints when given injections or giving blood).
  • Female who is pregnant (confirmed by positive serum β-HCG pregnancy test prior to baseline) or lactating.
  • Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device).
  • Sexually active men with partners of child bearing potential not using barrier contraception during the trial and for a period of three months thereafter.
  • Participation in a clinical trial of an investigational agent within 30 days prior to the screening visit.
  • Prior and concomitant therapy with medications which may interfere with the objectives of the study, including drugs that cause photosensitivity or skin pigmentation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00979745

Layout table for location information
HUS:n Iho-ja allergiasairaala (Skin and Allergy Hospital)
Helsinki, Finland
Centre Français des Porphyries, Hôpital Louis Mourier
Colombes, Cedex, France, 92701
Department of Dermatology , Heinrich-Heine-University Duesseldorf
Duesseldorf, Germany, 40225
Beaumont Hospital, Department of Dermatology
Dublin, Ireland, 9
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands
Erasmus Medical Center
Rotterdam, Netherlands
United Kingdom
St Woolos Hospital
Newport, Wales, United Kingdom
Photobiology Unit - Hope Hospital, University of Manchester
Manchester, United Kingdom, M6 8HD
Sponsors and Collaborators
Clinuvel Pharmaceuticals Limited
Layout table for investigator information
Principal Investigator: Alex Anstey, MBBS, FRCP St Woolos Hospital, Newport
Principal Investigator: Jorge Frank, MD, PhD Academisch Ziekenhuis Maastricht
Principal Investigator: Raili Kauppinen, MD, PhD University Central Hospital of Helsinki
Principal Investigator: Eric JG Sijbrands, MD, PhD Erasmus Medical Center
Principal Investigator: Jean-Charles Deybach, MD. PhD Centre Francais des Porphyries, Hopital Louis Mourier, Colombes, France
Principal Investigator: Sandra Hanneken, MD Heinrich-Heine Universität, Düsseldorf, Germany
Principal Investigator: Gillian M Murphy, MD PhD Beaumont Hospital, Dublin, Ireland
Principal Investigator: Lesley E Rhodes, MD PhD Hope Hospital, University of Manchester, UK
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Clinuvel Pharmaceuticals Limited
ClinicalTrials.gov Identifier: NCT00979745    
Other Study ID Numbers: CUV029
First Posted: September 18, 2009    Key Record Dates
Results First Posted: October 12, 2021
Last Update Posted: October 12, 2021
Last Verified: September 2021
Keywords provided by Clinuvel Pharmaceuticals Limited:
Erythropoietic Protoporphyria
Additional relevant MeSH terms:
Layout table for MeSH terms
Protoporphyria, Erythropoietic
Porphyrias, Hepatic
Liver Diseases
Digestive System Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Metabolic Diseases
Dermatologic Agents